HC Wainwright Weighs in on Unity Biotechnology, Inc.’s Q1 2024 Earnings (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for Unity Biotechnology in a research report issued to clients and investors on Tuesday, April 16th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.

Unity Biotechnology Trading Down 1.0 %

Shares of UBX stock traded down $0.02 during trading hours on Wednesday, hitting $1.51. 28,480 shares of the company were exchanged, compared to its average volume of 88,311. The business has a 50 day moving average of $1.66 and a two-hundred day moving average of $1.78. Unity Biotechnology has a 52 week low of $1.50 and a 52 week high of $3.82. The company has a market capitalization of $25.25 million, a PE ratio of -0.51 and a beta of 0.87.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP bought a new position in Unity Biotechnology in the first quarter valued at $32,000. Virtu Financial LLC grew its position in Unity Biotechnology by 25.4% in the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock valued at $35,000 after purchasing an additional 12,681 shares in the last quarter. Jane Street Group LLC bought a new position in Unity Biotechnology in the fourth quarter valued at $37,000. Schonfeld Strategic Advisors LLC bought a new position in Unity Biotechnology in the fourth quarter valued at $38,000. Finally, Commonwealth Equity Services LLC grew its position in Unity Biotechnology by 53.1% in the first quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock valued at $39,000 after purchasing an additional 8,499 shares in the last quarter. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.